News Daily News Side Effects of Statins Might Be Overstated: CTT Collaboration Michael O'Riordan February 12, 2026
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Daily News UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy Michael O'Riordan January 20, 2023
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News Heterozygous FH Diagnosed Late, Remains Undertreated Michael O'Riordan September 13, 2021
News Daily News Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD Michael O'Riordan September 22, 2020
News Daily News Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol Yael L. Maxwell January 28, 2020